NHS Services (Access)

Jim Shannon Excerpts

Wednesday 15th October 2014 Commons Chamber

[Jim Shannon (Strangford) (DUP)]

The motion is entitled “Access to NHS services” and I wish to comment on four categories of the NHS where services can be improved. Today we have heard one of the central themes of the next Westminster election on 7 May next year, because the battleground will clearly be the NHS. We have heard different opinions from both sides of the Chamber about the best way forward.

Parkinson’s disease is a progressive neurological condition that affects 127,000 people in the UK with an average age of 50 to 60. One person in every 500 has Parkinson’s disease, and there is no prospect of a person’s condition improving over time as there is currently no cure. Medication is the main treatment for the symptoms of Parkinson’s disease, and many people require multiple doses at specific times throughout the day. People with Parkinson’s who are admitted to hospitals are often prevented from managing their own medication, or are not given it in time. That leads to a deterioration in their condition, or even to permanent harm. It is clear that that costs the NHS some £20 million a year and that it is down to medication mismanagement in hospitals. It is a simple matter of receiving medication in time. What steps is the Minister taking to ensure that people with Parkinson’s always receive their medication on time in hospital, which in turn would mean that patients could return home sooner and that those costs could be greatly reduced? We talk about access to NHS services, but we need to know about funding, too.

Other hon. Members, including the hon. Member for Norwich North (Chloe Smith), have referred to Alzheimer’s. The numbers are horrific. Some 856,000 people in the UK have it: 720,000 in England; 45,000 in Wales; 70,000 in Scotland; and 21,000 in Northern Ireland. It will cost the UK £26 billion a year. Yet again, the question is: can access to NHS services happen? The costs are astronomical. How does the Minister plan to prepare for providing the necessary services in the years to come, perhaps at a reduced cost, and ever mindful of the access to the NHS services we all wish to have?

My third concern is diabetes. It is a great concern to many. It has been referred to in the Chamber and other places as a ticking time bomb that will cost the NHS the most money. It is also a question of access to services. I declare an interest as a type 2 diabetic—other hon. Members have the same problem. Diabetes UK says that, in this year alone, 280,000 people will be diagnosed with diabetes, which is the equivalent of the population of Newcastle—if we want to put the problem into perspective and relate it to a town or a city, that is the figure. The number of people living with type 1 and type 2 diabetes has increased throughout the UK: by 33% in Northern Ireland; by 25% in England; by 20% in Wales; and by 18% in Scotland. Some 738 people are diagnosed with type 2 diabetes per day.

The cost is significant. A report on diabetes in the NHS estimates a total cost of £3.5 billion per annum, or £9.6 million per day. An estimated 10% of the NHS budget is spent on diabetes, which is some £286 a second. The problem is funding and access to services. How do we ensure that people who are diabetic access NHS services?

A health survey in Northern Ireland—I am sure the figures are equivalent for the rest of the UK on the mainland—showed that some 62% of adults were classified as overweight or obese. The interesting thing that worries me a wee bit is children. Some 19% of children were reported to be overweight, and a further 6% were reported to be obese. When it comes to access to NHS treatment, what steps is the Minister taking to address childhood obesity and diet?

My final point is on cancer drugs. A central theme of the motion is cancer referrals and treatment waiting times. The problem impacts not only on those on the mainland, but on those of us in Northern Ireland and on our access to cancer drugs, despite Northern Ireland being an integral part of the United Kingdom and despite it being covered by the work of the National Institute for Health and Care Excellence, unlike Scotland, for example. Patients in Northern Ireland do not have access to 40 cancer drugs simply because of their postcodes.

In my discussions with Jim Wells, the Minister who has responsibility for health in Northern Ireland, he has referred to access in Northern Ireland to the individual funding request, whereby a consultant can submit an application for one of those 40 drugs on a patient’s behalf. However, there is a high hurdle, known as the “exceptionality test”, which is very hard to pass. Many consultants in Northern Ireland do not apply to use the IFR and know that the application will not pass. What discussions has the Minister had with the Minister in Northern Ireland on that? It is totally unfair. I am baffled and find it totally unacceptable that the access to treatments for my constituents who are diagnosed with cancer—they live in Northern Ireland and pay UK tax—is far more limited than it is for patients in the rest of the UK. With that in mind, I believe it is time for the provision of cancer drugs across the whole United Kingdom, and to the 331,487 people in the UK with cancer, irrespective of postcode.